HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Suspends Domestic Inspections As Staff Work Remotely In Covid-19 Response

Executive Summary

Exceptions will be made for inspections of facilities manufacturing medically necessary products, such as products to treat and prevent Covid-19, the disease caused by the virus, and breakthrough products such as cancer treatments.

You may also be interested in...



US FDA's Review Of Records Submitted By Foreign OTC Drug Firms Reveals GMP Problems

Turkish firm Gulsah Uretim Kozmetik Sanayi Anonim Sirketi is latest OTC manufacturer warned GMP violations based on records submitted in response to requests CDER submitted in March and April 2020.

What The FDA’s Inspections Q&A Guidance Really Means: It’s Time To Offer Virtual Inspections

Compliance experts see possibilities in offering video tours as the FDA offers “holistic” approach to assessing sites during pandemic.

Complete Response Letters In Lieu Of Inspections: What To Expect During COVID-19

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS149815

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel